Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.

International journal of mycobacteriology - 1 Apr 2024

Shabani Samira, Farnia Poopak, Ghanavi Jalaledin, Velayati Ali Akbar, Farnia Parissa

Abstract excerpt

BACKGROUND: Pharmacogenetic research has led to significant progress in understanding how genetic factors influence drug response in tuberculosis (TB) treatment. One ongoing challenge is the variable occurrence of adverse drug reactions in some TB patients. Previous studies have indicated that genetic variations in the N-acetyltransferase 2 (NAT2) and solute carrier organic anion transporter family member 1B1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoniazid

Share to Liver-Specific Organic Anion Transporter 1

Share to Pharmacogenomic Testing

Share to Rifampin

Share to Tuberculosis

Source

Identifiers

PMID: 38916393
DOI: 10.4103/ijmy.ijmy_106_24

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.PMID 38916393Read ↗

Genetic polymorphisms and adverse reactions to antituberculosis therapySemantic proximity Read ↗

Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidenceSemantic proximity Read ↗

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH StudySemantic proximity Read ↗

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohortSemantic proximity Read ↗

Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis.Semantic proximity Read ↗

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.Semantic proximity Read ↗

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.Semantic proximity Read ↗

In-silico functional prediction of novel tuberculosis pharmacogenetic variants and NAT2 phenotype prediction in African populationsSemantic proximity Read ↗

Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.Semantic proximity Read ↗

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort.Semantic proximity Read ↗

A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosingSemantic proximity Read ↗

Improving the reporting of pharmacogenetic studies to facilitate evidence synthesis : anti-tuberculosis drug-related toxicity as an exampleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.